News | January 11, 2023
Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
To create leading company developing medicines targeting metalloenzymes
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Subscribe To Our Newsletter & Stay Updated
